Ventilator Hyperinflation and Hemodynamics (VHI-HD)

August 12, 2020 updated by: Centro Universitário Augusto Motta

Hemodynamic Repercussions of Ventilator Hyperinflation Using Volume-controlled Ventilation: a Randomized Controlled Trial

Ventilator hyperinflation (VHI) has been shown to be effective in improving respiratory mechanics, secretion removal, and gas exchange in mechanically ventilated patients; however, the literature is scarce concerning its safety and adverse effects. Thus, the aim of this study is to compare the hemodynamic repercussions of VHI in volume-controlled mode. In a randomized, controlled and crossover design, 24 mechanically ventilated patients will undergo 2 modes of ventilator hyperinflation (with and without an inspiratory pause) and a control intervention. Cardiac output, cardiac index, mean arterial pressure, pulmonary vascular resistance, systolic volume and other hemodynamic variables will be recorded during the interventions.

Study Overview

Detailed Description

Background: ventilator hyperinflation (VHI) has been shown to be effective in improving respiratory mechanics, secretion removal, and gas exchange in mechanically ventilated patients; however, the literature is scarce concerning its safety and adverse effects. Thus, the aim of this study is to compare the hemodynamic repercussions of VHI in volume-controlled mode.

Methods: in a randomized, controlled and crossover design, 24 mechanically ventilated patients will undergo 2 modes of ventilator hyperinflation (with and without an inspiratory pause of 2 seconds) and a control intervention. For the VHI interventions, the inspiratory flow will be set at 20 Lpm, and tidal volume will be increased until a peak pressure of 40cmH2O is achieved. During the control intervention, the patients will remain in volume-control ventilation with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. The interval between interventions (washout) will be of 10 minutes or more, according to the time needed to recover the cardiac index to baseline values (maximum difference of 10%). Cardiac output, cardiac index, mean arterial pressure, pulmonary vascular resistance, systolic volume and other hemodynamic variables will be recorded during the interventions by using impedance cardiography.

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Rio De Janeiro
      • Niterói, Rio De Janeiro, Brazil, 24241-002
        • Hospital Santa Martha

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients under mechanical ventilation for more than 48h

Exclusion Criteria:

  • mucus hypersecretion (defined as the need for suctioning < 2-h intervals),
  • absence of respiratory drive,
  • atelectasis,
  • severe bronchospasm,
  • positive end expiratory pressure > 10cmH2O,
  • PaO2-FiO2 relationship < 150,
  • mean arterial pressure < 60mmHg,
  • inotrope requirement equivalent to >15 ml/h total of adrenaline and noradrenalin,
  • intracranial pressure > 20mmHg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Baseline Mechanical Ventilation
The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
Experimental: VHI With Inspiratory Pause
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
Experimental: VHI Without Inspiratory Pause
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Cardiac Output
Time Frame: Baseline (before) and 10 minutes after the onset of VHI modesBasel
Estimation of cardiac output variation using thoracic bioimpedance
Baseline (before) and 10 minutes after the onset of VHI modesBasel

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Cardiac Index
Time Frame: Baseline (before) and 10 minutes after the onset of VHI modes
Estimation of cardiac index variation using thoracic bioimpedance
Baseline (before) and 10 minutes after the onset of VHI modes
Change in Vascular pulmonary resistance
Time Frame: Baseline (before) and 10 minutes after the onset of VHI modes
Estimation of vascular pulmonary resistance variation using thoracic bioimpedance
Baseline (before) and 10 minutes after the onset of VHI modes
Change in Systolic Volume
Time Frame: Baseline (before) and 10 minutes after the onset of VHI modes
Estimation of systolic volume variation using thoracic bioimpedance
Baseline (before) and 10 minutes after the onset of VHI modes
Change in Mean Arterial Pressure
Time Frame: Baseline (before) and 10 minutes after the onset of VHI modes
Recording of mean arterial pressure variation using an automatic noninvasive device
Baseline (before) and 10 minutes after the onset of VHI modes
Change in Cardiac Output II
Time Frame: Baseline (before) and 5 minutes after the end of VHI modes
Estimation of cardiac output variation using thoracic bioimpedance
Baseline (before) and 5 minutes after the end of VHI modes
Change in Cardiac Index II
Time Frame: Baseline (before) and 5 minutes after the end of VHI modes
Estimation of cardiac index variation using thoracic bioimpedance
Baseline (before) and 5 minutes after the end of VHI modes
Change in Vascular pulmonary resistance II
Time Frame: Baseline (before) and 5 minutes after the end of VHI modes
Estimation of vascular pulmonary resistance variation using thoracic bioimpedance
Baseline (before) and 5 minutes after the end of VHI modes
Change in Systolic Volume II
Time Frame: Baseline (before) and 5 minutes after the end of VHI modes
Estimation of systolic volume variation using thoracic bioimpedance
Baseline (before) and 5 minutes after the end of VHI modes
Change in Mean Arterial Pressure II
Time Frame: Baseline (before) and 5 minutes after the end of VHI modes
Recording of mean arterial pressure variation using an automatic noninvasive device
Baseline (before) and 5 minutes after the end of VHI modes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Fernando Guimaraes, PhD, Centro Universitário Augusto Motta

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2017

Primary Completion (Actual)

September 20, 2018

Study Completion (Actual)

September 30, 2018

Study Registration Dates

First Submitted

May 13, 2018

First Submitted That Met QC Criteria

June 4, 2018

First Posted (Actual)

June 15, 2018

Study Record Updates

Last Update Posted (Actual)

August 14, 2020

Last Update Submitted That Met QC Criteria

August 12, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Failure

Clinical Trials on Baseline Mechanical Ventilation

Subscribe